Vail Scientific
Vail Scientific develops a point-of-care, non‑invasive diagnostic system that measures exhaled nitric oxide (NO) to enable faster sepsis screening in triage settings. The company conducts clinical feasibility and proof‑of‑concept trials, publishes peer‑reviewed results, partners with device development and manufacturing organizations for device design-for-manufacturing and scale-up, and is pursuing regulatory clearance.
Industries
Nr. of Employees
small (1-50)
Vail Scientific
Minneapolis, Minnesota, United States
Patents
Apparatus and method for the determination of endothelial dysfunction and sepsis risk using nitric oxide concentrations in exhaled breath
US-12539073-B1
View Details
Apparatus and method for the determination of endothelial dysfunction and sepsis risk using nitric oxide concentrations in exhaled breath
US-12539073-B1
View DetailsProducts
Prototype handheld breath-based sepsis screening device
A portable, handheld point-of-care breath analyzer that measures exhaled nitric oxide and provides a rapid screening result intended for triage workflows.
VSNO technology
A real-time, non-invasive, point-of-care sepsis detection device using proprietary Nitric Oxide (NO) technology for early detection of sepsis.
Prototype handheld breath-based sepsis screening device
A portable, handheld point-of-care breath analyzer that measures exhaled nitric oxide and provides a rapid screening result intended for triage workflows.
VSNO technology
A real-time, non-invasive, point-of-care sepsis detection device using proprietary Nitric Oxide (NO) technology for early detection of sepsis.
Services
Design and conduct of feasibility and proof‑of‑concept clinical trials in emergency departments and clinical sites to evaluate diagnostic performance.
Collaboration with contract design, development, and manufacturing partners to redesign devices, implement DFM, and produce units for verification studies.
Design and conduct of feasibility and proof‑of‑concept clinical trials in emergency departments and clinical sites to evaluate diagnostic performance.
Collaboration with contract design, development, and manufacturing partners to redesign devices, implement DFM, and produce units for verification studies.
Expertise Areas
- Point-of-care diagnostic device development
- Breath-based biomarker measurement
- Clinical trial management and diagnostic accuracy studies
- Diagnostic algorithm and score development
Key Technologies
- Exhaled nitric oxide (NO) sensing
- Handheld breath analyzer hardware
- Low-ppb gas detection
- Embedded device electronics and firmware
News & Updates
Peer‑reviewed clinical trial describing the diagnostic accuracy of exhaled nitric oxide combined with vital signs (VSNO score) for detection of bacterial infection and sepsis in emergency department patients.
Announcement of a $2.0 million investment to support expansion of clinical trials, regulatory progression, and commercialization of a point‑of‑care sepsis screening device.
Report on partnership with a contract design, development, and manufacturing organization to redesign the handheld breath analyzer, reduce size, and prepare units for verification testing and manufacturing planning.
Industry press coverage describing the redesigned handheld breath test and its role in earlier sepsis screening.
Article on development of a portable breath analyzer to screen for sepsis risk by measuring exhaled nitric oxide and plans to bring screening to triage.
Completed an initial feasibility trial and a larger proof‑of‑concept trial evaluating exhaled nitric oxide measurements in emergency department patients and healthy volunteers.
Peer‑reviewed clinical trial describing the diagnostic accuracy of exhaled nitric oxide combined with vital signs (VSNO score) for detection of bacterial infection and sepsis in emergency department patients.
Announcement of a $2.0 million investment to support expansion of clinical trials, regulatory progression, and commercialization of a point‑of‑care sepsis screening device.
Report on partnership with a contract design, development, and manufacturing organization to redesign the handheld breath analyzer, reduce size, and prepare units for verification testing and manufacturing planning.
Industry press coverage describing the redesigned handheld breath test and its role in earlier sepsis screening.
Article on development of a portable breath analyzer to screen for sepsis risk by measuring exhaled nitric oxide and plans to bring screening to triage.
Completed an initial feasibility trial and a larger proof‑of‑concept trial evaluating exhaled nitric oxide measurements in emergency department patients and healthy volunteers.